所有图片(1)
About This Item
经验公式（希尔记法）:
C13H12N2O5S
CAS号:
分子量:
308.31
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
推荐产品
等级
pharmaceutical primary standard
API类
nimesulide
制造商/商品名称
EDQM
应用
pharmaceutical (small molecule)
包装形式
neat
储存温度
2-8°C
SMILES字符串
CS(NC1=C(OC2=CC=CC=C2)C=C([N+]([O-])=O)C=C1)(=O)=O
InChI
1S/C13H12N2O5S/c1-21(18,19)14-12-8-7-10(15(16)17)9-13(12)20-11-5-3-2-4-6-11/h2-9,14H,1H3
InChI key
HYWYRSMBCFDLJT-UHFFFAOYSA-N
正在寻找类似产品? 访问 产品对比指南
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Nimesulide for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
生化/生理作用
高选择性环氧化酶-2 抑制剂。
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他说明
Sales restrictions may apply.
警示用语：
Danger
危险声明
危险分类
Acute Tox. 3 Oral
储存分类代码
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
H Suleyman et al.
Current medicinal chemistry, 15(3), 278-283 (2008-03-13)
In this review it is shown that nimesulide, a selective cyclooxigenase-2 (COX-2) inhibitor, is different from other selective COX-2 inhibitors and classical non-steroidal anti-inflammatory drugs (NSAIDs). The anti-inflammatory effect mechanism of nimesulide (inhibition of inflammatory mediators) is similar to other
Francesco Guido Mangano et al.
Clinical oral implants research, 25(8), 933-940 (2013-04-30)
The aim of this study was to evaluate the long-term outcome of short (8-mm) locking-taper implants supporting single crowns in the posterior regions and to analyze the influence of different factors on implant survival and implant-crown success rates. Between June
C Mattia et al.
Minerva medica, 101(4), 285-293 (2010-10-30)
The first marketing authorization for nimesulide was approved in Italy in 1985. After one quarter of a century we evaluate its peculiar characteristics compared with other NSAIDs. Nimesulide is the only NSAID related to the arylsulfonamide class and is a
U A Boelsterli
International journal of clinical practice. Supplement, (128)(128), 30-36 (2002-08-09)
Nimesulide, similar to other nonsteroidal anti-inflammatory drugs (NSAIDs), has been associated with rare and unpredictable but serious hepatic adverse reactions. The low incidence (about 0.1 case per 100,000 treated patients, no more than with most other NSAIDs), estimated from the
Eduardo Candelario-Jalil
Pharmacological research, 57(4), 266-273 (2008-04-29)
Nimesulide is a preferential inhibitor of cyclooxygenase-2 (COX-2) and it is one of the most prescribed non-steroidal anti-inflammatory drugs (NSAID) worldwide. Nimesulide was recently shown to have neuroprotective properties in animal models of acute neurologic injury. In particular, nimesulide is
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门